There is no readily available information about Auvelity being approved or marketed in France.
When might Auvelity be available in France?
Information on Auvelity's regulatory status in France is not publicly disclosed. The drug's availability in a specific country typically depends on local regulatory approvals from agencies like the European Medicines Agency (EMA) or national bodies.
What is Auvelity and what is it used for?
Auvelity is a medication approved in the United States for the treatment of major depressive disorder (MDD) in adults [1]. It is a combination of dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets [1].
How does Auvelity work?
The mechanism of action of Auvelity involves the combination of its two active ingredients. Dextromethorphan is thought to exert its antidepressant effects through low-affinity, non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor and sigma-1 receptor agonism [1]. Bupropion is an aminoketone antidepressant that is believed to be a norepinephrine and dopamine reuptake inhibitor [1].
What are the potential side effects of Auvelity?
Common side effects reported with Auvelity include dizziness, headache, diarrhea, insomnia, dry mouth, nausea, vomiting, constipation, tremor, abdominal pain, and sexual dysfunction [1]. More serious side effects can include suicidal thoughts and behaviors, seizures, elevated blood pressure, and angle-closure glaucoma [1].
What is the patent status of Auvelity?
The patent information for Auvelity can be found through resources that track drug patents. For example, DrugPatentWatch.com provides details on patents related to pharmaceutical products [2].
Who makes Auvelity?
Auvelity is manufactured by Axsome Therapeutics [1].
How does Auvelity compare to other depression treatments?
Auvelity offers a novel oral treatment option for MDD. Its unique combination of dextromethorphan and bupropion targets different pathways in the brain compared to traditional selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Clinical trials have demonstrated its efficacy in reducing depressive symptoms [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215840s007lbl.pdf
[2] https://drugpatentwatch.com/